Akari Therapeutics Company Insiders
| AKTX Stock | USD 1.18 0.01 0.85% |
Akari Therapeutics' insiders are aggressively buying. The analysis of insiders' sentiment of trading Akari Therapeutics PLC stock suggests that vertually all insiders are extremely bullish at this time. Akari Therapeutics employs about 9 people. The company is managed by 24 executives with a total tenure of roughly 125 years, averaging almost 5.0 years of service per executive, having 0.38 employees per reported executive.
| Gur Roshwalb CEO CEO, Director |
| David Solomon CEO CEO |
Akari Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2015-09-18 | Mark S Cohen | Acquired 1055600 @ 0.19 | View | ||
| 2014-04-15 | Sabby Management, Llc | Acquired 20100 @ 5.03 | View | ||
| 2014-04-11 | Sabby Management, Llc | Acquired 2575 @ 5.35 | View | ||
| 2014-04-08 | Sabby Management, Llc | Acquired 68404 @ 5.59 | View | ||
| 2014-04-02 | Sabby Management, Llc | Acquired 28207 @ 6.22 | View | ||
| 2014-03-27 | Sabby Management, Llc | Acquired 16203 @ 6.66 | View | ||
| 2014-03-24 | Sabby Management, Llc | Acquired 11100 @ 6.83 | View |
Monitoring Akari Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Akari |
Akari Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.1551) % which means that it has lost $1.1551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.8143) %, meaning that it created substantial loss on money invested by shareholders. Akari Therapeutics' management efficiency ratios could be used to measure how well Akari Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Akari Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 45.89 in 2024, whereas Return On Tangible Assets are likely to drop (2.41) in 2024. At this time, Akari Therapeutics' Intangible Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to rise to 0 in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.Common Stock Shares Outstanding is likely to drop to about 4.7 M in 2024. Net Loss is likely to drop to about (21 M) in 2024
Akari Therapeutics Workforce Comparison
Akari Therapeutics PLC is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 7,329. Akari Therapeutics adds roughly 9.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Akari Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akari Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akari Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Akari Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akari Therapeutics Notable Stakeholders
An Akari Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Akari Therapeutics often face trade-offs trying to please all of them. Akari Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Akari Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gur Roshwalb | CEO, Director | Profile | |
| Rachelle Jacques | CEO President | Profile | |
| David Solomon | CEO | Profile | |
| Ray Prudo | Chairman of the Board | Profile | |
| Nigel Hernandez | Vice President - Worldwide Regulatory Affairs | Profile | |
| Dov Elefant | CFO | Profile | |
| Allan Shaw | Independent Director | Profile | |
| Stuart Ungar | Non-Executive Director | Profile | |
| Donald Williams | Director | Profile | |
| Mark Cohen | Director | Profile | |
| David Byrne | Director | Profile | |
| Clive Richardson | Chief Operations Officer and Director | Profile | |
| James Hill | Non-Executive Director | Profile | |
| Robert Ward | Director | Profile | |
| Michael Grissinger | Director | Profile | |
| Peter Feldschreiber | Director | Profile | |
| Torsten Hombeck | Chief Officer | Profile | |
| Annie Mack | Financial Controller | Profile | |
| Wendy CPA | Interim Officer | Profile | |
| Miles Nunn | Chief Officer | Profile | |
| MD III | Executive Officer | Profile | |
| Ray MD | Ex Chairman | Profile | |
| BethAnne Lang | Senior Affairs | Profile | |
| Melissa BradfordKlug | Chief Officer | Profile |
About Akari Therapeutics Management Performance
The success or failure of an entity such as Akari Therapeutics PLC often depends on how effective the management is. Akari Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Akari management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Akari management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.30) | (2.41) | |
| Return On Capital Employed | 73.39 | 77.06 | |
| Return On Assets | (2.30) | (2.41) | |
| Return On Equity | 43.70 | 45.89 |
The data published in Akari Therapeutics' official financial statements usually reflect Akari Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Akari Therapeutics PLC. For example, before you start analyzing numbers published by Akari accountants, it's critical to develop an understanding of what Akari Therapeutics' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Akari Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akari Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Akari Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Akari Therapeutics PLC. Please utilize our Beneish M Score to check the likelihood of Akari Therapeutics' management manipulating its earnings.
Akari Therapeutics Workforce Analysis
Traditionally, organizations such as Akari Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Akari Therapeutics within its industry.Akari Therapeutics Manpower Efficiency
Return on Akari Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 417K | |
| Working Capital Per Employee | 197.1K | |
| Working Capital Per Executive | 73.9K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Akari Stock analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Akari Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akari Therapeutics. If investors know Akari will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akari Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Return On Assets (1.16) | Return On Equity (12.81) |
The market value of Akari Therapeutics PLC is measured differently than its book value, which is the value of Akari that is recorded on the company's balance sheet. Investors also form their own opinion of Akari Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akari Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akari Therapeutics' market value can be influenced by many factors that don't directly affect Akari Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akari Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akari Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akari Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.